Quantitative imaging tool to tell tumor recurrence from radiation effects in glioblastoma
Official title: Quantitative imaging phenotypic classifier for distinguishing radiation effects from tumor recurrence in Glioblastoma
Funded at University of Wisconsin-Madison · NIH-11377043 · Data updated 2026-11-12
A non-invasive MRI-based classifier helps doctors distinguish recurrent glioblastoma from treatment-related changes to spare patients unnecessary biopsy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Wisconsin-Madison NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | June 30, 2022 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $710,498 |
| NIH project number | 5R01CA264017-05 |
| Project ID | NIH-11377043 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with glioblastoma who have new suspicious MRI lesions after standard treatment and are candidates for decision-making about biopsy or further treatment.
✕Less likely to help
Patients without post-treatment imaging changes or those not undergoing biopsy decisions may not benefit directly.
What this research studies
This project develops an image-based classifier using routine MRI scans to differentiate tumor recurrence from radiation-related changes in glioblastoma patients. It builds on a previously developed classifier and aims to achieve high diagnostic accuracy without invasive procedures. The work involves analyzing MRI features and validating the tool against biopsy results to support clinical decision-making after standard GBM treatment.
Why it matters
Potential benefit: If successful, the tool could reduce unnecessary brain biopsies and speed up correct treatment decisions for glioblastoma patients.
How similar studies have gone: Preliminary work has shown ~85% accuracy in distinguishing recurrence from radiation effects, with prior IRRisC features reported as promising but requiring broader validation.
Where this research is happening
-
University of Wisconsin-Madison
Madison, United States Active
Researchers
- Principal investigator: Tiwari, Pallavi — University of Wisconsin-Madison
- Study coordinator: Tiwari, Pallavi
Related research
Other NIH-funded projects on the same topics.
-
Cell-level look at glioblastoma edges and tumors that come back
This project uses fresh tumor slices and single-cell methods to find which cell types at the tumor core and edge respond to different drugs for people with glioblastoma.
-
Personalized therapeutic cancer vaccine for glioblastoma to help survival
A new, patient-focused vaccine approach uses a patient's own tumor cells to help the immune system recognize and fight glioblastoma, with the goal of longer survival and fewer recurrences.
-
How radiation affects brain cells and glioblastoma recurrence
This study looks at how radiation therapy affects the brain and might help glioblastoma, a tough type of brain cancer, come back after treatment, with the hope that what we learn can lead to better ways to fight this disease.
-
Better telling apart tumor growth from treatment effects in Glioblastoma
This project aims to create a new way to tell if changes on an MRI scan for Glioblastoma patients are new tumor growth or harmless side effects from radiation treatment.
-
Keloid recurrence study using multi-omics in diverse patients
A research effort will look at why keloids come back after surgery, especially in African American patients, using comprehensive molecular data from patient samples.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.